Muneer H. Abidi

4.9k total citations · 2 hit papers
92 papers, 2.7k citations indexed

About

Muneer H. Abidi is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Muneer H. Abidi has authored 92 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 44 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Muneer H. Abidi's work include Multiple Myeloma Research and Treatments (32 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Protein Degradation and Inhibitors (13 papers). Muneer H. Abidi is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Protein Degradation and Inhibitors (13 papers). Muneer H. Abidi collaborates with scholars based in United States, Poland and Hungary. Muneer H. Abidi's co-authors include Brian G.M. Durie, Bart Barlogie, Robert Z. Orlowski, Angela Dispenzieri, Antje Hoering, Rachael Sexton, S. Vincent Rajkumar, Mohan C. Thakuri, Stephen P. Kahanic and Frederic J. Reu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Muneer H. Abidi

89 papers receiving 2.7k citations

Hit Papers

Bortezomib with lenalidomide and dexamethasone versus len... 2015 2026 2018 2022 2016 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
    2016 594 citations Brian G.M. Durie, Antje Hoering et al. profile →
  2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Muneer H. Abidi United States 22 1.5k 1.5k 977 691 321 92 2.7k
Peter Mollee Australia 25 841 0.6× 936 0.6× 997 1.0× 514 0.7× 444 1.4× 180 2.5k
G.J. Ossenkoppele Netherlands 34 1.6k 1.0× 1.1k 0.8× 783 0.8× 812 1.2× 677 2.1× 84 3.3k
Stig Lenhoff Sweden 26 2.0k 1.3× 1.0k 0.7× 877 0.9× 244 0.4× 365 1.1× 87 2.7k
Jacques‐Olivier Bay France 25 891 0.6× 721 0.5× 702 0.7× 290 0.4× 386 1.2× 151 2.4k
Muzaffar H. Qazilbash United States 34 2.7k 1.8× 1.4k 0.9× 1.2k 1.3× 383 0.6× 508 1.6× 312 3.9k
Marı́a Dolores Caballero Spain 32 1.1k 0.7× 1.2k 0.8× 407 0.4× 1.4k 2.0× 586 1.8× 74 2.8k
Steven N. Wolff United States 23 769 0.5× 953 0.6× 410 0.4× 393 0.6× 382 1.2× 53 2.1k
Michael J. Barnett Canada 30 1.8k 1.2× 698 0.5× 474 0.5× 712 1.0× 1.0k 3.2× 115 2.9k
Joon Ho Moon South Korea 24 807 0.5× 561 0.4× 655 0.7× 391 0.6× 282 0.9× 175 1.9k
Selim Corbacioglu Germany 29 1.4k 0.9× 643 0.4× 527 0.5× 176 0.3× 428 1.3× 105 2.7k

Countries citing papers authored by Muneer H. Abidi

Since Specialization
Citations

This map shows the geographic impact of Muneer H. Abidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muneer H. Abidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muneer H. Abidi more than expected).

Fields of papers citing papers by Muneer H. Abidi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muneer H. Abidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muneer H. Abidi. The network helps show where Muneer H. Abidi may publish in the future.

Co-authorship network of co-authors of Muneer H. Abidi

This figure shows the co-authorship network connecting the top 25 collaborators of Muneer H. Abidi. A scholar is included among the top collaborators of Muneer H. Abidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muneer H. Abidi. Muneer H. Abidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Malinis, Maricar, G. Gan, Muneer H. Abidi, et al.. (2025). Frailty by Chart Review Can Predict Infection in Kidney Transplant Recipients: A Multicenter Study through the AST IDCOP. American Journal of Transplantation. 25(8). S163–S163. 1 indexed citations
2.
3.
Nademanee, Auayporn, Anna Sureda, Patrick J. Stiff, et al.. (2018). Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting. Biology of Blood and Marrow Transplantation. 24(11). 2354–2359. 27 indexed citations
4.
Knight, Jennifer M., Karen L. Syrjala, Navneet S. Majhail, et al.. (2016). Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biology of Blood and Marrow Transplantation. 22(12). 2256–2263. 17 indexed citations
5.
Sweetenham, John, Jan Walewski, Tamás Masszi, et al.. (2016). Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biology of Blood and Marrow Transplantation. 22(3). S36–S37. 12 indexed citations
6.
7.
Nandagopal, Lakshminarayanan, Muneer H. Abidi, Lois Ayash, et al.. (2014). Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant. Blood. 124(21). 5904–5904.
8.
Vij, Ravi, Shaji Kumar, Mei-Jie Zhang, et al.. (2014). Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 21(2). 335–341. 42 indexed citations
9.
Deol, Abhinav, Judith Abrams, Ashiq Masood, et al.. (2013). Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplantation. 48(8). 1112–1116. 20 indexed citations
10.
Al‐Kadhimi, Zaid, Muneer H. Abidi, Abhinav Deol, et al.. (2013). Lower Lymphocyte Count At Day 30 Predicts Worse Overall Survival with Tacrolimus and Mycophenophelate Mofetil Use for Gvhd Prophylaxis: A Large Retrospective Analysis. Biology of Blood and Marrow Transplantation. 19(2). S198–S199. 1 indexed citations
11.
Lum, Lawrence G., Archana Thakur, Qin Liu, et al.. (2013). CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation. 19(6). 925–933. 32 indexed citations
12.
Abidi, Muneer H., Rishi Agarwal, Nishant Tageja, et al.. (2012). A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function. Biology of Blood and Marrow Transplantation. 19(1). 56–61. 17 indexed citations
13.
Abidi, Muneer H., Judith Abrams, Lois Ayash, et al.. (2012). Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. Journal of Chemotherapy. 24(3). 167–172. 8 indexed citations
14.
Atallah, Ehab, Judith Abrams, Lois Ayash, et al.. (2010). Long term follow‐up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. American Journal of Hematology. 85(8). 579–583. 3 indexed citations
15.
Zonder, Jeffrey A., John Crowley, Mohamad A. Hussein, et al.. (2010). Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 116(26). 5838–5841. 149 indexed citations
16.
Wood, Gary S., Janet Poulik, Roy Baynes, et al.. (2008). High-dose Chemotherapy and Adoptive Immunotherapy in the Treatment of Recurrent Pediatric Brain Tumors. Neuropediatrics. 39(3). 151–156. 21 indexed citations
17.
Peres, Edward, Polly E. Kintzel, Roger Dansey, et al.. (2008). Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagulation & Fibrinolysis. 19(3). 203–207. 24 indexed citations
18.
Abidi, Muneer H., et al.. (2007). Non‐bacterial infections in allogeneic non‐myeloablative stem cell transplant recipients. Transplant Infectious Disease. 9(1). 3–10. 9 indexed citations
19.
Abidi, Muneer H., et al.. (2006). The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. Hematological Oncology. 24(3). 164–165. 6 indexed citations
20.
Ibrahim, R., Edward Peres, Roger Dansey, et al.. (2004). Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation—Associated Toxicity. Annals of Pharmacotherapy. 38(6). 1053–1059. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Mollee Breakdown of academic impact, for papers by G.J. Ossenkoppele Breakdown of academic impact, for papers by Stig Lenhoff Breakdown of academic impact, for papers by Jacques‐Olivier Bay Breakdown of academic impact, for papers by Muzaffar H. Qazilbash Breakdown of academic impact, for papers by Marı́a Dolores Caballero Breakdown of academic impact, for papers by Steven N. Wolff Breakdown of academic impact, for papers by Michael J. Barnett Breakdown of academic impact, for papers by Joon Ho Moon Breakdown of academic impact, for papers by Selim Corbacioglu
Rankless by CCL
2026